{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:57:59Z","timestamp":1791903479006,"version":"4.3.4"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["16-26849S"],"award-info":[{"award-number":["16-26849S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EFSA-CDN","award":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000841"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000841"]}]},{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"crossref","award":["SVV 260 416"],"award-info":[{"award-number":["SVV 260 416"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.bcp.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T01:55:37Z","timestamp":1533261337000},"page":"22-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment"],"prefix":"10.1016","volume":"156","author":[{"given":"Eva","family":"Novotn\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neslihan","family":"B\u00fck\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Flaxov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etela","family":"Koukl\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Louvarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Ws\u00f3l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2018.08.001_b0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.bcp.2018.08.001_b0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4161\/cbt.19589","article-title":"Cyclin dependent kinases in cancer: potential for therapeutic intervention","volume":"13","author":"Canavese","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2018.08.001_b0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","article-title":"Inhibitors of cyclin-dependent kinases as cancer therapeutics","volume":"173","author":"Whittaker","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"13","key":"10.1016\/j.bcp.2018.08.001_b0020","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/1078-0432.CCR-04-2264","article-title":"In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202","volume":"11","author":"Raynaud","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2018.08.001_b0025","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.10738","article-title":"In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)","volume":"102","author":"McClue","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2018.08.001_b0030","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2174\/092986730609220401152358","article-title":"ATP-site directed inhibitors of cyclin-dependent kinases","volume":"6","author":"Gray","year":"1999","journal-title":"Curr. Med. Chem."},{"issue":"5376","key":"10.1016\/j.bcp.2018.08.001_b0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.281.5376.533","article-title":"Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors","volume":"281","author":"Gray","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2018.08.001_b0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3892\/ijmm.2017.2989","article-title":"The Cdc2\/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18\/stathmin in non-small cell lung cancer cells in vitro","volume":"40","author":"Chen","year":"2017","journal-title":"Int. J. Mol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2018.08.001_b0045","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.leu.2403295","article-title":"Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells","volume":"18","author":"Hahntow","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bcp.2018.08.001_b0050","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-08-1748","article-title":"Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer","volume":"15","author":"Hsieh","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2018.08.001_b0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ijc.23938","article-title":"Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model","volume":"124","author":"Appleyard","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2018.08.001_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083467","article-title":"Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro","volume":"8","author":"Cihalova","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bcp.2018.08.001_b0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","article-title":"Role of anthracyclines in the era of targeted therapy","volume":"7","author":"Cortes-Funes","year":"2007","journal-title":"Cardiovasc. Toxicol."},{"issue":"3","key":"10.1016\/j.bcp.2018.08.001_b0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0006-2952(99)00322-6","article-title":"Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction","volume":"59","author":"Ax","year":"2000","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2018.08.001_b0075","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1389200216888150915112039","article-title":"Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines","volume":"16","author":"Edwardson","year":"2015","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.bcp.2018.08.001_b0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/mol.53.1.141","article-title":"Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells","volume":"53","author":"Marbeuf-Gueye","year":"1998","journal-title":"Mol. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2018.08.001_b0085","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1124\/dmd.108.022251","article-title":"Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver","volume":"36","author":"Kassner","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2018.08.001_b0090","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/jpet.110.173179","article-title":"Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin","volume":"335","author":"Bains","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2018.08.001_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2008.06.858","article-title":"Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3","volume":"181","author":"Novotna","year":"2008","journal-title":"Toxicol. Lett."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2018.08.001_b0100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbi.2010.12.016","article-title":"Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase","volume":"191","author":"Skarka","year":"2011","journal-title":"Chem. Biol. Interact."},{"issue":"3","key":"10.1016\/j.bcp.2018.08.001_b0105","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bcp.2015.05.005","article-title":"Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases","volume":"96","author":"Hofman","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.001_b0110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/1471-2407-12-381","article-title":"Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization","volume":"12","author":"Heibein","year":"2012","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2018.08.001_b0115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0006-2952(95)02121-3","article-title":"Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells","volume":"51","author":"Soldan","year":"1996","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.08.001_b0120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/jpet.113.206805","article-title":"A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin","volume":"347","author":"Bains","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2018.08.001_b0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10565-006-0143-8","article-title":"In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity","volume":"23","author":"Menna","year":"2007","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.bcp.2018.08.001_b0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.taap.2016.01.003","article-title":"Inhibition of human anthracycline reductases by emodin \u2013 A possible remedy for anthracycline resistance","volume":"293","author":"Hintzpeter","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2018.08.001_b0135","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.taap.2014.04.027","article-title":"Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3","volume":"278","author":"Hofman","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2018.08.001_b0140","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/FPC.0b013e32832c484b","article-title":"Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance","volume":"19","author":"Veitch","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"issue":"1","key":"10.1016\/j.bcp.2018.08.001_b0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00686485","article-title":"Anthracyclines and their C-13 alcohol metabolites \u2013 Growth-inhibition and DNA damage following incubation with human tumor-cells in culture","volume":"30","author":"Kuffel","year":"1992","journal-title":"Cancer Chemoth. Pharm."},{"issue":"2","key":"10.1016\/j.bcp.2018.08.001_b0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-011-1638-4","article-title":"Targeting low molecular weight cyclin E (LMW-E) in breast cancer","volume":"132","author":"Nanos-Webb","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.bcp.2018.08.001_b0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2133\/dmpk.DMPK-13-RG-051","article-title":"Deeper insight into the reducing biotransformation of bupropion in the human liver","volume":"29","author":"Skarydova","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bcp.2018.08.001_b0160","doi-asserted-by":"crossref","unstructured":"J.E. Debreczeni, P. Lukacik, K. Kavanagh, E. Dubinina, J. Bray, S. Colebrook, A. Haroniti, A. Edwards, C. Arrowsmith, M. Sundstrom, F. von Delft, O. Gilead, U. Oppermann., Structure of the Aflatoxin Aldehyde Reductase in Complex with Nadph. doi: 10.2210\/pdb2BP1\/pdb.","DOI":"10.2210\/pdb2bp1\/pdb"},{"key":"10.1016\/j.bcp.2018.08.001_b0165","doi-asserted-by":"crossref","DOI":"10.1007\/s00204-018-2258-0","article-title":"Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile","author":"Novotna","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bcp.2018.08.001_b0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13321-015-0067-5","article-title":"Calculating an optimal box size for ligand docking and virtual screening against experimental and predicted binding pockets","volume":"7","author":"Feinstein","year":"2015","journal-title":"J. Cheminform."},{"issue":"18","key":"10.1016\/j.bcp.2018.08.001_b0175","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1093\/bioinformatics\/btu364","article-title":"CAVER Analyst 1.0: graphic tool for interactive visualization and analysis of tunnels and channels in protein structures","volume":"30","author":"Kozlikova","year":"2014","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.bcp.2018.08.001_b0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"16","key":"10.1016\/j.bcp.2018.08.001_b0185","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2018.08.001_b0190","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/mabi.201200303","article-title":"In vitro transfection mediated by dendrigraft poly(L-lysines): the effect of structure and molecule size","volume":"13","author":"Hofman","year":"2013","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.bcp.2018.08.001_b0195","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jsbmb.2014.04.005","article-title":"Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors","volume":"143","author":"Skarydova","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2018.08.001_b0200","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2018.08.001_b0205","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"issue":"7","key":"10.1016\/j.bcp.2018.08.001_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22071192","article-title":"Assessment of enzyme inhibition: a review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs","volume":"22","author":"Ramsay","year":"2017","journal-title":"Molecules"},{"issue":"19","key":"10.1016\/j.bcp.2018.08.001_b0215","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.1073\/pnas.0913302107","article-title":"Structural study of TcaR and its complexes with multiple antibiotics from Staphylococcus epidermidis","volume":"107","author":"Chang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"33","key":"10.1016\/j.bcp.2018.08.001_b0220","doi-asserted-by":"crossref","first-page":"E6942","DOI":"10.1073\/pnas.1707752114","article-title":"Structural basis of subunit selectivity for competitive NMDA receptor antagonists with preference for GluN2A over GluN2B subunits","volume":"114","author":"Lind","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2018.08.001_b0225","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/1471-2105-7-316","article-title":"CAVER: a new tool to explore routes from protein clefts, pockets and cavities","volume":"7","author":"Petrek","year":"2006","journal-title":"BMC Bioinf."},{"issue":"5","key":"10.1016\/j.bcp.2018.08.001_b0230","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00280-011-1800-z","article-title":"Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia","volume":"69","author":"Krogh-Madsen","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2018.08.001_b0235","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-61779-080-5_34","article-title":"Analysis of drug interactions","volume":"731","author":"Bijnsdorp","year":"2011","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2018.08.001_b0240","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.bcp.2018.08.001_b0245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","article-title":"A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days","volume":"96","author":"Benson","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2018.08.001_b0250","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10637-017-0443-2","article-title":"Metabolic carbonyl reduction of anthracyclines \u2013 Role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents","volume":"35","author":"Piska","year":"2017","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2018.08.001_b0255","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jsbmb.2013.05.012","article-title":"AKR1C3 as a target in castrate resistant prostate cancer","volume":"137","author":"Adeniji","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"20","key":"10.1016\/j.bcp.2018.08.001_b0260","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1158\/0008-5472.CAN-04-0446","article-title":"17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer","volume":"64","author":"Oduwole","year":"2004","journal-title":"Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2018.08.001_b0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mrfmmm.2008.12.010","article-title":"The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis","volume":"662","author":"Birtwistle","year":"2009","journal-title":"Mutat. Res."},{"key":"10.1016\/j.bcp.2018.08.001_b0270","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/1471-2407-10-672","article-title":"Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression","volume":"10","author":"Dozmorov","year":"2010","journal-title":"BMC Cancer"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2018.08.001_b0275","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mce.2008.04.004","article-title":"AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K\/Akt proliferative signaling pathway in human prostate cancer cells","volume":"289","author":"Wang","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2018.08.001_b0280","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1749-6632.2009.03700.x","article-title":"Steroid hormone transforming aldo-keto reductases and cancer","volume":"1155","author":"Penning","year":"2009","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2018.08.001_b0285","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bcp.2016.03.025","article-title":"Carbonyl reduction of warfarin: identification and characterization of human warfarin reductases","volume":"109","author":"Malatkova","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2018.08.001_b0290","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.110.036996","article-title":"Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor","volume":"39","author":"Ghosal","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2018.08.001_b0295","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1124\/jpet.105.091587","article-title":"Tibolone metabolism in human liver is catalyzed by 3alpha\/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily","volume":"316","author":"Steckelbroeck","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3\u20135","key":"10.1016\/j.bcp.2018.08.001_b0300","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jsbmb.2011.12.002","article-title":"Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily","volume":"129","author":"Jin","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2018.08.001_b0305","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/00498254.2012.720048","article-title":"Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro","volume":"43","author":"Skarydova","year":"2013","journal-title":"Xenobiotica"},{"issue":"13","key":"10.1016\/j.bcp.2018.08.001_b0310","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.4155\/fmc-2017-0114","article-title":"Small molecule inhibitors for acute myeloid leukemia: where is the field heading?","volume":"9","author":"Trippier","year":"2017","journal-title":"Future Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2018.08.001_b0315","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/1535-7163.353.3.3","article-title":"Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis","volume":"3","author":"Raynaud","year":"2004","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bcp.2018.08.001_b0320","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.phrs.2011.11.017","article-title":"Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone","volume":"65","author":"Hofman","year":"2012","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.bcp.2018.08.001_b9000","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: a free tool to discover chemistry for biology","volume":"52","author":"Irwin","year":"2012","journal-title":"J. Chem. Inf. Model."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T22:22:03Z","timestamp":1720477323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218303204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":65,"alternative-id":["S0006295218303204"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.08.001","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}